Background: Ability to manage urges to smoke is fundamental to maximizing the chances of success in smoking cessation. Previous studies have linked a higher dose of nicotine in nicotine replacement therapy to a higher success rate for smoking cessation. Thus, this study was performed to compare relief of urges to smoke, up until 5 h following treatment with a new 6 mg nicotine gum versus currently marketed 4 mg nicotine gum.
Methods: This was a randomized crossover clinical study. Following 12 h of abstinence from smoking, either one 6 mg or one 4 mg nicotine gum was given to 240 healthy adult smokers. Thereafter, urges to smoke were scored on a 100 mm Visual Analogue Scale repeatedly over 5 h.
Results: The reductions in urges to smoke over the first 1 and 3 h after administration were statistically significantly greater with 6 mg than 4 mg gum, (p < 0.005). A 50% reduction in perceived urges to smoke was reached in 9.4 min with 6 mg gum compared to 16.2 min with 4 mg gum (median values). The median duration of a 50% or more reduction in VAS urges to smoke score was 111 min with the 6 mg gum, versus 74 min for the 4 mg gum.
Conclusion: This study provides evidence that the 6 mg nicotine gum provided a greater reduction, faster and longer relief of urges to smoke than the 4 mg nicotine gum.
Trial Registration: EudraCT Number: 2010-023268-42. Study was first entered in EudraCT 2011-02-23.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873734 | PMC |
http://dx.doi.org/10.1186/s40360-019-0368-9 | DOI Listing |
J Pain
January 2025
Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 2400 Pratt Street, Durham, NC 27705, United States. Electronic address:
Chronic pain affects ~20% of the adult population and is associated with smoking. Smoking and pain worsen each other in the long term, but short-term temporal associations between smoking and pain throughout the day are unclear. Understanding these relationships may inform strategies for managing comorbid smoking and pain.
View Article and Find Full Text PDFBMJ Open Sport Exerc Med
December 2024
Institute of General Practice, Centre for Health and Society, Addiction Research and Clinical Epidemiology Unit, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany.
Background: Physical inactivity and tobacco smoking remain the leading causes of morbidity and mortality worldwide. In Germany, smoking prevalence is high at around 30%, and only 45% achieve the WHO recommendation for physical activity (PA). Understanding how smoking and physical inactivity co-occur can inform interventions targeting these behaviours.
View Article and Find Full Text PDFNicotine Tob Res
December 2024
Addictions and related-Research Group, Sangath, Porvorim, Goa, India.
Introduction: Tobacco consumption is a leading cause of mortality globally. Eighty percent of these deaths occur in low- and middle-income countries (LMICs). Despite this, there is a large treatment gap due to both demand and supply-side barriers.
View Article and Find Full Text PDFSci Rep
November 2024
Department of Medicine, Internal Medicine, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
BMC Rheumatol
November 2024
Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Background: Healthy lifestyle habits (regular physical activity, a healthy diet, no smoking and non-hazardous alcohol consumption) alongside pharmacological treatment can lower the risk of cardiovascular diseases and improve symptoms and quality of life in patients with rheumatoid arthritis (RA). Therefore, healthcare professionals in rheumatology care are urged to discuss lifestyle habits with all patients. The aim of this study was to explore patients' perceptions of lifestyle discussions in early rheumatology care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!